Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Insights
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

January 6, 2023

Aclaris Therapeutics Provides 2023 Outlook

November 29, 2022

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

November 22, 2022

Aclaris Therapeutics Announces Key Leadership Transitions

Events

Jan 11, 2023
5:15 PM EST

Aclaris Therapeutics at 41st Annual J.P. Morgan Healthcare Conference

Nov 29, 2022
9:30 AM EST

Aclaris Therapeutics at 34th Annual Piper Sandler Healthcare Conference

Nov 16, 2022
5:00 PM GMT

Aclaris Therapeutics at Jefferies London Healthcare Conference

Feature Presentation

Aclaris Therapeutics Company Overview – January 2023

Aclaris Therapeutics Company Overview – January 2023

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2023 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.